Priming or Boosting Plasmodium falciparum Transmission-Blocking Responses With Recombinant Vaccines or Gametocyte Extract.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40503613.
- Also identified by DOI 10.1093/infdis/jiaf318.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Plasmodium falciparum infection can induce antibody responses to the parasitic, gametocyte-expressed antigens Pfs48/45 and Pfs230. Retrospective analysis of healthy individuals from malaria-endemic Mali showed increasing prevalence of antibodies to these antigens from infancy to age 17 years, an expected response to malaria exposure. This supports examining the immune interplay between gametocyte exposure and vaccination with these antigens as transmission-blocking vaccine (TBV) candidates. Recombinant Pfs48/45 and Pfs230 were formulated with a liposome-display vaccine adjuvant system. In mice primed with either antigen, subsequent gametocyte extract (GE) exposure significantly boosted antibody responses. Dose-dependent GE exposure induced transmission-reducing activity (TRA) in Pfs48/45-primed mice but not in naive controls. Conversely, GE-primed mice exhibited enhanced TRA after Pfs48/45 vaccination. These findings demonstrate bidirectional immune priming and highlight the potential for TBVs to elicit stronger TRA responses upon subsequent natural malaria exposure and/or in endemic areas in individuals with preexisting antibodies to TBV antigens.
Medical subject headings
- Malaria Vaccines
- Malaria, Falciparum
- Plasmodium falciparum
- Antigens, Protozoan